For Indian women with advanced ovarian cancer, the conversation around HIPEC, hyperthermic intraperitoneal chemotherapy, sits in a strange place. Patients have heard of it. Many oncologists are cautious about it. A few centres in metro cities offer it; most don’t. Cost estimates vary by lakhs depending on who you ask. And in the middle of this, families are trying to make a decision that will materially affect outcome and quality of life.
This article is meant to clarify what HIPEC actually does, who it is appropriate for in the Indian context, and how patient selection has matured over the last few years. It is not a sales pitch for the procedure, HIPEC is the right answer for a defined group of patients and the wrong answer for many others.
What HIPEC is, in plain terms
After a gynaecological oncosurgeon performs cytoreductive surgery (CRS), the operation that removes all visible tumour from the abdominal cavity, HIPEC is the next step, performed during the same anaesthetic. Heated chemotherapy fluid is circulated through the abdomen for roughly 60 to 90 minutes at around 41–43 °C, with continuous monitoring.
Two things make this delivery method different from standard intravenous chemotherapy:
- Direct contact. The chemotherapy bathes any microscopic disease left after surgery, rather than diluting through systemic circulation first.
- Heat synergy. Hyperthermia enhances the cytotoxic effect of certain agents (cisplatin, mitomycin-C, oxaliplatin) and damages cancer cells more selectively than at body temperature.
The mental model: surgery removes the visible disease, HIPEC sterilises the microscopic residue. HIPEC is not a substitute for complete cytoreduction. It is a way to make complete cytoreduction last longer.
What the evidence actually supports
The strongest evidence base in gynaecological oncology, the OVHIPEC-1 trial (NEJM, 2018), established that for women with Stage III epithelial ovarian cancer receiving interval cytoreductive surgery after neoadjuvant chemotherapy, adding HIPEC produced a meaningful, durable improvement in both recurrence-free survival and overall survival. That trial has been the basis for incorporating HIPEC into NCCN guidelines as a category-2A option in this specific patient subset.
The keyword in that sentence is “specific.” HIPEC is not a routine addition to all ovarian cancer surgery. The evidence does not support it for early-stage disease, it remains under investigation for primary debulking, and its role in recurrent ovarian cancer continues to be defined by ongoing trials.
Who actually benefits, the patient profile
In contemporary Indian gynaecological oncology practice, HIPEC is most clearly indicated for:
- Stage III epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Receiving interval cytoreductive surgery after 3 cycles of neoadjuvant chemotherapy
- Where the surgical team is confident of achieving complete (CC-0) or near-complete (CC-1) cytoreduction
- Without significant cardiopulmonary or renal comorbidity that would make the prolonged operative time risky
For selected patients with recurrent platinum-sensitive disease who have a long disease-free interval and resectable recurrence, HIPEC may also be appropriate, typically as part of a multidisciplinary tumour board decision rather than a default offer.
Who doesn’t benefit, and why this matters
Equally important are the patients HIPEC is not appropriate for:
- Stage I or II disease (no evidence of benefit; adds morbidity)
- Patients with unresectable disease at exploration (HIPEC after incomplete cytoreduction does not reproduce trial outcomes)
- Patients with significant peritoneal carcinomatosis from primary mucinous ovarian cancer (different biology; benefit unclear)
- Patients whose performance status or organ reserve would not tolerate the additional 90 minutes of intraperitoneal therapy plus the recovery profile
The reason this matters is that HIPEC adds operative time, requires specialised equipment, and increases peri-operative monitoring needs. In the wrong patient, those costs are not offset by benefit. The discipline of appropriate patient selection is what separates a HIPEC programme that improves outcomes from one that just performs more procedures.
The Indian cost question
HIPEC pricing in India has historically been opaque, with quotes ranging from ₹4 lakh to ₹12 lakh depending on hospital, insurance status, and what is bundled in. Patients trying to make a decision deserve clearer information.
In broad terms, the total cost of cytoreductive surgery plus HIPEC in a major Indian tertiary centre, including operating theatre, anaesthesia, HIPEC consumables, ICU stay, and ward stay, typically falls between ₹6 lakh and ₹10 lakh for an uncomplicated course. Most major insurers (TPA-based and reimbursement-based) cover the package; the proportion covered depends on the policy. Premium-room upgrades and complications add to this.
Patients should expect to receive a written package estimate before consenting. Reputable centres provide this in writing. The single most important variable in the cost, and in the outcome, is the surgical completeness achievable, which depends on the surgical team’s experience and the institutional ICU and rehabilitation infrastructure rather than on geographic prestige.
For Indian patients in Gujarat, Rajasthan, and Madhya Pradesh, HIPEC surgery in Ahmedabad has become an established option that obviates the need to travel to Mumbai or Delhi. This has improved access materially, especially for families who cannot relocate for the 10–14 days of peri-operative care.
Why ERAS, Enhanced Recovery After Surgery, changed the picture
One of the most underappreciated developments in CRS+HIPEC over the last five years has been the systematic adoption of ERAS protocols. Pre-ERAS, the median ICU stay was 3–5 days and the median total stay was 12–16 days. With well-implemented ERAS, both metrics drop substantially, and the morbidity profile improves without any change in the procedure itself.
The case for adopting and evolving ERAS in Indian CRS+HIPEC practice is no longer theoretical, the protocols are well-defined, the implementation is feasible at Indian tertiary centres, and the outcome differences are measurable. For patients, this changes what HIPEC actually feels like to undergo: fewer drains, earlier mobilisation, earlier feeding, less post-operative pain, and a meaningfully shorter recovery window.
The bowel anastomosis question, a technical note that matters
For patients whose cytoreductive surgery involves bowel resection, which is common in Stage III disease, a quietly important technical question is whether the bowel anastomosis is performed before or after HIPEC.
There are good arguments on both sides. Performing the anastomosis after HIPEC reduces theoretical chemotherapy-related compromise of the anastomotic site, but adds operative time after a long procedure. Performing it before HIPEC simplifies the surgical sequence, but exposes the new anastomosis to heated chemotherapy.
This decision benefits from intra-operative judgment and from surgeon experience with both sequences. It is the kind of decision a patient won’t need to weigh in on, but it is the kind of decision that distinguishes high-volume specialist centres from those performing HIPEC occasionally.
Questions to ask before consenting to HIPEC
For patients and families approaching this decision, here is a short list of questions that consistently produce useful information:
- What is the team’s annual volume of CRS+HIPEC procedures?
- What is the team’s documented rate of complete cytoreduction (CC-0) for cases like mine?
- Is there a multidisciplinary tumour board that has reviewed my case before this recommendation?
- What is the ICU and recovery infrastructure at this centre?
- What is the written cost estimate, including the worst-case complication scenario?
- What chemotherapy regimen will be used for HIPEC, and on what basis?
- What is the planned ERAS protocol, and what does my expected recovery timeline look like?
These are not aggressive questions. They are the questions every reasonable HIPEC centre is prepared to answer.
The bottom line
HIPEC is a high-value intervention for a narrow band of patients with advanced ovarian cancer, primarily Stage III epithelial disease at the point of interval cytoreductive surgery. For those patients, the addition of HIPEC to complete cytoreduction produces durable survival benefit that justifies the additional operative complexity and cost.
For everyone else, HIPEC is either unproven or inappropriate. The discipline of patient selection, the surgical team’s experience, the ICU and ERAS infrastructure, and the candour around cost are what separate a HIPEC programme worth seeking out from one worth declining.
If you are weighing this decision, ask the questions above. The answers will tell you most of what you need to know.
About the author
This article was authored by Dr. Nishtha Tripathi Patel (MBBS, DGO, DNB, Fellowship in Gynaecological Oncology, ESGO-certified), an ESGO-certified gynaecological oncosurgeon in Ahmedabad with 12+ years of experience and published academic work on CRS+HIPEC, PIPAC, ICG-guided sentinel lymph node biopsy, robotic peritonectomy, and surgery for recurrent ovarian cancer. She consults at Sterling Hospitals (Sindhubhavan), KD Hospital, and Welcare Speciality Hospital, Ahmedabad.
Comments are closed.